Sarat Chandarlapaty, MD
Enriched profileBreast Medical Oncologist, Memorial Sloan Kettering Cancer Center; Naddisy Foundation Chair in Breast Cancer Research · Memorial Sloan Kettering Cancer Center
Sarat Chandarlapaty is Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center; Naddisy Foundation Chair in Breast Cancer Research at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 696 publications with 27,118 citations (h-index 75); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 15 Oct 2026
Sarat Chandarlapaty, M.D., PH.D., is Breast Medical Oncologist, Memorial Sloan Kettering Cancer Center. The public record shows 696 publications with 27,118 citations (h-index 75), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Estrogen and related hormone effects. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 10 companies, 9 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · Nature
- Top research focus: Advanced Breast Cancer Therapies
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 63 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 160.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 15 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
- Daiichi Sankyo Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor52.9%Exemestane59%Letrozole41%Part D<11 patientsKinase inhibitor47.1%Ibrance54%Tukysa46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
9 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- MSK SPORE in Genomic Instability in Breast Cancer
Sloan-Kettering Inst Can Research
FY2026$1,807,170P50CA247749 - Overcoming Resistance to Targeted Therapy in Breast Cancer
Sloan-Kettering Inst Can Research
FY2026$1,056,000R35CA305347 - Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.
Sloan-Kettering Inst Can Research
FY2026$520,487R01CA296285
Congress activity
Updated 15 Oct 2026
163 congress contributions (2007–2025) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 432: Evolution of drug tolerance and resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
AACR Annual Meeting
AACR2025Co-author - Abstract 724: Target identification for antibody-drug-conjugate (ADC) therapy in biliary tract cancers (BTC)
AACR Annual Meeting
AACR2025Co-author - Abstract LB280: Resistance to trastuzumab deruxtecan (T-DXd) in breast cancer via loss of HER2 expression and binding
AACR Annual Meeting
AACR2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.
Cancer discovery
Article2026 - Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer.
Nature genetics
Erratum2026
Most-cited works
by citation count (OpenAlex)- 01OncoKB: A Precision Oncology Knowledge BaseArticle2,738 citations2017
- 02ESR1 ligand-binding domain mutations in hormone-resistant breast cancerArticle1,279 citations2013
- 03Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate CancerArticle1,202 citations2011
- 04Unlocking the potential of antibody–drug conjugates for cancer therapyArticle1,119 citations2021
- 05The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersArticle1,028 citations2018
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sarat-chandarlapaty-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/sarat-chandarlapaty-8968a0216
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
ourmbclife.org/episodes/road-to-a-cure-dr-sarat-chanderlapaty-md-phd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ourmbclife.org ↗ - Spotify
bcrf.org/blog/investigating-breast-cancer-underlying-biology-drug-resistance
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - X / Twitter
x.com/MSKCancerCenter/status/1923404460706984237
- X / Twitter
x.com/MSKCancerCenter/status/2046750900769669152
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
- Chair
BCRF Scientific Advisory Board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Editorial Board
npj Breast Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nature.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- BCRF podcast episode
"Investigating Breast Cancer: The Underlying Biology of Drug Resistance"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Podcast guest
"Road to a Cure" episode, Our MBC Life
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ourmbclife.org ↗ - Video profile
"Meet Sarat Chandarlapaty: Breast Medical Oncologist at MSK" (YouTube)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles